Psychedelics Archives - Page 33 of 68

2 minute read

Psyched Clinical Trials: Australian Univ. Pursues MDMA, MEAI Compound About To Set Off

April 20, 2:48 PM

Monash University Engages LaNeo MDMA Australian Monash University’s psychedelics research lab has contracted MDXX-class molecules developer PharmAla Biotech to manufacture and supply its clinical-grade MDMA LaNeo for an upcoming Phase 2 clinical study.

CMND

2 minute read

Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up

By Lara Goldstein

April 20, 2:24 PM

Orphan and rare diseases drug company Lobe Sciences Ltd. (OTCQB: LOBEF) is set to acquire Altemia & Company LLC.

LOBEF

2 minute read

Stress, Anxiety, PTSD: 2 NASDAQ-Listed Drug Developers Advance Psychedelic-Inspired Meds

By Lara Goldstein

April 20, 9:12 AM

Psychedelics biotech Silo Pharma Inc. (NASDAQ: SILO) and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD.

DRUG

2 minute read

Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism

By Lara Goldstein

April 20, 9:02 AM

The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started <

NMLSF

2 minute read

Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn’s New Phase 3 Study

By Lara Goldstein

April 19, 11:25 AM

The research partnership between UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) and the University of Exeter for an upcoming

AWKNF

3 minute read

EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps

By Lara Goldstein

April 19, 10:04 AM

In the current psychedelics landscape, one of the most important topics is compound legality. While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what should investors consider when looking at a prospective business?

AWKNF

3 minute read

Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More

By Lara Goldstein

April 17, 4:14 PM

Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules

ATAI

2 minute read

Novel Compound Begins Clinical Testing For Potential Treatment Of Multiple Sclerosis

By Lara Goldstein

April 17, 3:52 PM

FSD Pharma Inc. (NASDAQ: HUGE) has dosed the first subjects in its first clinical trial assessing the New Chemical Entity (NCE) Lucid-21-302, or Lucid-MS, targetting multiple sclerosis.

HUGE

2 minute read

80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial

By Lara Goldstein

April 17, 1:26 PM

Psychedelics biopharma company Mind Medicine Inc.’s (NASDAQ: MNMD) shared positive topline data from an advanced clinical trial evaluating its lysergide (aka LSD) for the treatment of Major Depressive Disorder (MDD) on Friday — just a couple of days before the 80th anniversary of the discov

MNMD

2 minute read

Atai Advances R-Ketamine Through Phase 1 Bridging Study, Update And Near-Term Expectations

By Lara Goldstein

April 14, 7:29 PM

Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous

ATAI